Maravai LifeSciences Holdings, Inc. Deferred Federal Income Tax Expense (Benefit)
Maravai LifeSciences Holdings, Inc. (MRVI) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-26
- Maravai LifeSciences Holdings, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00.
- Maravai LifeSciences Holdings, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Maravai LifeSciences Holdings, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $663.97M, a 1563.08% increase from fiscal 2022.
- Maravai LifeSciences Holdings, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was $39.92M, a 9.19% increase from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $663.97M 10-K · filed 2026-02-26 |
| 2022-12-31 | $39.92M 10-K · filed 2025-03-18 |
| 2021-12-31 | $36.56M 10-K · filed 2024-02-29 |
| 2020-12-31 | -$3.92M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$1.22M 10-K · filed 2022-03-01 |